Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-13

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the Epithelial Lining Fluid concentrations and permeability of Intravenous Meropenem-Pralubactam(Meropenem/FL058) in China Healthy Adult Participants. The main question it aims to answer is:

• \[question 1\] : What are the concentrations of meropenem and Pralubactam in plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) at each time point

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944

NCT01934205

Infections, Bacterial

COMPLETED PHASE1

An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia

NCT00648726

Pneumonia

COMPLETED PHASE3

Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit

NCT04363060

COVID-19 Pneumonia

UNKNOWN PHASE3

Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

NCT02393586

Tuberculosis

COMPLETED PHASE1

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

NCT04870606

Efficacy and Safety

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravenous Meropenem-Pralubactam

Group Type EXPERIMENTAL

Meropenem-Pralubactam

Intervention Type DRUG

The study is designed to enroll approximately 16 healthy participants. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Meropenem-Pralubactam

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meropenem-Pralubactam

The study is designed to enroll approximately 16 healthy participants. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Meropenem-Pralubactam

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, aged 18-45 years
* Body mass index (BMI): 19-28 kg/m² , with body weight ≥50 kg.
* Pulmonary function at screening:

1. Forced expiratory volume in 1 second (FEV₁) measured/predicted \>80%
2. Forced vital capacity (FVC) measured/predicted \>80%
3. All other ventilation and diffusion parameters normal or with no clinical significance.
* Participant capability:

1. Ability to communicate effectively with investigators
2. Willingness to comply with study procedures
3. Voluntary participation with acceptance of bronchoalveolar lavage (BAL)
4. Provision of written informed consent.
* Reproductive planning:

1. No pregnancy, sperm/egg donation plans from signing informed consent through 28 days after last dose
2. Participant and partner must use protocol-approved contraception.

Exclusion Criteria

* Hypersensitivity to cephalosporins or carbapenem antibiotics.
* History or current diagnosis of respiratory system diseases.
* History or current diagnosis of coagulation disorders.
* Clinically significant diseases in cardiovascular, endocrine, neurological, digestive, hematological, metabolic, or psychiatric systems judged by the investigator to interfere with study outcomes.
* History of smoking or positive nicotine test during screening.
* Prior surgery involving pharynx, trachea/bronchi, or lungs.
* Drug abuse history within 1 year prior to screening or positive urine drug screen at screening.
* Alcohol intake \>14 units/week on average within 6 months prior to screening.
* Participation in other clinical trials with investigational drugs/devices within 3 months prior to screening.
* Blood donation/loss ≥400 mL or blood product transfusion within 3 months prior to screening.
* Respiratory infections (bacterial/fungal/viral) within 2 weeks prior to screening (e.g., upper/lower respiratory tract infections).
* Use of any medication/vaccination within 14 days prior to screening or planned vaccination during the study.
* Clinically significant abnormalities in physical examination, 12-lead ECG, or imaging at screening per investigator's judgment.
* Pregnancy, lactation, or positive serum pregnancy test at screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes